Drug Type Small molecule drug |
Synonyms Famitinib, Famitinib maleate + [1] |
Mechanism FGFRs antagonists(Fibroblast growth factor receptors antagonists), PDGFR antagonists(Platelet-derived growth factor receptor antagonists), VEGFR antagonists(Vascular endothelial growth factor receptor antagonists) + [2] |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
RegulationBreakthrough Therapy (CN) |
Molecular FormulaC23H27FN4O2 |
InChIKeyGKEYKDOLBLYGRB-LGMDPLHJSA-N |
CAS Registry1044040-56-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Uterine Cervical Cancer | NDA/BLA | CN | 06 Dec 2023 | |
Advanced Cervical Carcinoma | Phase 3 | - | - | |
Non-squamous non-small cell lung cancer | Phase 3 | - | - | |
PD-L1 positive Non-Small Cell Lung Cancer | Phase 3 | - | - | |
Gastrointestinal Stromal Tumors | Preclinical | CN | 07 Sep 2020 | |
Recurrent Lung Non-Squamous Non-Small Cell Carcinoma | Preclinical | CN | 01 Jun 2016 | |
Recurrent Cervical Cancer | Discovery | CN | 23 Jul 2021 | |
Advanced Colorectal Adenocarcinoma | Discovery | CN | 01 Jan 2015 | |
Colorectal cancer recurrent | Discovery | CN | 01 Jan 2015 | |
Metastatic Colorectal Carcinoma | Discovery | CN | 01 Jan 2015 |
NCT04346381 (Pubmed) Manual | Phase 2 | Non-Small Cell Lung Cancer First line | 41 | (ngtbhhsyjz) = yenbrlqofn sudvyksdir (riyujtaria, 37.4 - 69.3) View more | Positive | 21 Feb 2024 | |
NCT04346381 (Literature) Manual | Phase 2 | Non-Small Cell Lung Cancer First line | 41 | (cuzlnydvbf) = itdlntwdzk lkelyzmzlf (kwqytvxhgb, 37.4 - 69.3) View more | Positive | 21 Feb 2024 | |
Phase 2 | 15 | (hfybonpnkh) = gfhcdbvtzv dczehzjuoz (ftblapquws, 21.3 - 73.4) View more | - | 07 Dec 2023 | |||
NCT05051865 (ASCO2023) Manual | Phase 2 | 18 | (pts experienced ICI) | (umqfpyppmn) = qqwynzmdmf ypugolaeyp (bkdnmhlmni ) View more | Positive | 31 May 2023 | |
Not Applicable | 11 | (qkllgqzvzh) = mrmbtbeznj lrxoegrnov (gfnxcryrge ) View more | Positive | 31 May 2023 | |||
Phase 2 | Non-Small Cell Lung Cancer First line | 41 | (vldjjrldgy) = nqkzqlzexv smgxjmjppk (xhbnfevmcx, 37.4 - 69.3) View more | Positive | 31 Mar 2023 | ||
Phase 2 | - | (arsakqrwwe) = znttoqdmqv dfhtqzolqe (kxzjxqpiuw, 22.9 - 57.9) | Positive | 08 Dec 2022 | |||
Phase 1 | - | 21 | (rxvncgspza) = sbqzngzhov hxlqgxiysr (tvcvalwswc ) | - | 15 Sep 2022 | ||
(rxvncgspza) = zupmvzfiwk hxlqgxiysr (tvcvalwswc ) | |||||||
NCT04346381 (ASCO2022) Manual | Phase 2 | 15 | (yremulqnal) = kaxzbmfvla ossuqiirfa (vatkyfivra, 11.8 - 61.6) View more | Positive | 02 Jun 2022 | ||
NCT04346381 (ASCO2022) Manual | Phase 2 | 44 | overall | (rupmjqjyri) = zbtxkaemou ppihbeveum (yxacbrpztw, 5.2 - 27.4) View more | Positive | 02 Jun 2022 | |
(colon cancer) | (ztbvenetlr) = eylqequfit ytbkqdugxi (sypamfshry, 17.7 - 71.1) View more |